In this edition: Genetically engineered babies, antidepressant misconceptions and the first new malaria drug in years.

A couple wagers time, hope and $300,000 on a quest for children. A 40-something woman and her spouse must decide whether to continue pursuing fertility treatments as costs pile up and their chances at pregnancy diminish.

Don’t worry about increasing your step count. Just take fewer, longer walks. A study found that walking in sessions of 15 minutes or more rather than in shorter bursts showed big health benefits.

Tech titans pursue genetically engineered babies, despite legal hurdles. Startups funded by some of the most powerful billionaires in Silicon Valley are pushing the boundaries of reproductive genetics, hoping to prevent diseases as well as improve the chances for a high IQ and other preferred traits.

Fermentation is having a moment. An increasing number of nutrition scientists and food companies want us to eat more fermented foods—such as yogurt, kimchi, sauerkraut and…Gut Nuts?

Misconceptions about antidepressants abound. Social media influencers tout them as lifestyle medications that can turn around your life, while Health Secretary Robert F. Kennedy Jr. says they’re more addictive than heroin. What’s the reality? Here are some answers.

A statin isn’t the only answer anymore to lowering cholesterol. Some patients have other lipid-reducing medicines available as options—and even more alternatives are on the horizon.

The first new malaria drug in years shows promise… Novartis said that a potential new treatment cured more than 99% of malaria cases in a late-stage study, and it may also be able to prevent the spread of drug resistance.

…as does a multiple sclerosis drug. Roche said its fenebrutinib drug candidate met primary goals in two late-stage trials, reducing attacks or delaying disability progression in two different forms of the disease.

Obesity drugs are about to go mass-market. Medicare coverage for drugs like Wegovy and Zepbound will cut the prices Big Pharma can charge but open the door to millions of new patients, writes David Wainer.

This email was compiled by WSJ’s Newsletters team. Get in touch by replying to this newsletter. Got a tip for us? Here’s how to submit.